Document is current
Any future updates will be listed below
-
Authors
Rowland, Catherine E. https://orcid.org/0000-0002-0064-8312
Newman, Hector
Martin, Tazmin T. https://orcid.org/0009-0008-0732-7379
Dods, Rachel
Bournakas, Nikolaos
Wagstaff, James M. https://orcid.org/0000-0002-9670-8075
Lewis, Nick
Stanway, Steven J.
Balmforth, Matthew
Kessler, Celia https://orcid.org/0000-0002-3729-0318
van Rietschoten, Katerine https://orcid.org/0000-0002-0360-8244
Bellini, Dom https://orcid.org/0000-0003-0576-3413
Roper, David I. https://orcid.org/0000-0003-0009-621X
Lloyd, Adrian J. https://orcid.org/0000-0002-4638-4586
Dowson, Christopher G. https://orcid.org/0000-0002-8294-8836
Skynner, Michael J. https://orcid.org/0000-0001-6586-9055
Beswick, Paul
Dawson, Michael J.
-
Funding
Funding for this research was provided by:
Innovate UK (971626Q1, 82975, MR/W003554/1)
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 16 May 2025
First Online: 28 May 2025
Competing interests
: The authors declare the following competing financial interest(s): C.E.R., C.K., H.N., K.v.R., M.J.S., N.L., N.B., S.J.S, T.T.M., and P.B. are shareholders and/or share option holders in Bicycle Therapeutics plc, the parent company of BicycleTx Ltd.
